Insomnia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Zolpidem is the fastest growing sector, North America is the largest market

The global insomnia treatment market is projected to expand significantly, rising from USD 3.82 billion in 2025 to USD 5.32 billion by 2031, demonstrating a compound annual growth rate of 5.68%. This market encompasses various pharmacological and non-pharmacological treatments aimed at addressing difficulties in falling and staying asleep. Key factors driving this growth include the increasing rates of stress and anxiety, a growing elderly population prone to sleep cycle disturbances, and greater public awareness of the serious health consequences of insufficient sleep. In 2024, for example, 12% of Americans had a chronic insomnia diagnosis, as reported by the American Academy of Sleep Medicine, highlighting a considerable patient population in need of effective treatments.

Despite these positive growth projections, the market faces considerable obstacles primarily related to the safety and dependency risks linked with traditional drug therapies. The risk of adverse side effects from the prolonged use of sedative-hypnotics poses a major challenge, potentially discouraging patients from adhering to treatment and limiting prescriptions by doctors. Furthermore, stringent regulatory scrutiny concerning drug safety and efficacy standards continues to complicate the approval of new products, which could hinder the market's rapid expansion.

Market Drivers

The increasing global prevalence of chronic sleep disorders is a primary driver fueling the insomnia treatment market, generating substantial and urgent demand for effective therapies. Contemporary lifestyles, which often blur the lines between professional and personal time, have led to a surge in sleep disturbances, requiring both medicinal and behavioral approaches worldwide. This growing burden is well-documented; a systematic review in Sleep Medicine Reviews (August 2025) estimated that 852 million adults globally suffer from insomnia disorder, highlighting a vast, diagnosed patient population. Concurrently, there is a strong shift in consumer perception, with sleep now recognized as a vital component of overall health; SingleCare reported in 2025 that 80% of adults globally aspire to improve their sleep, indicating extensive market potential beyond clinical patients to the broader wellness consumer.

Furthermore, technological innovations in digital therapeutics and sleep tracking are transforming the market by providing proven, non-pharmacological options to conventional sedatives. The industry is increasingly adopting prescription digital therapeutics (PDTs) that deliver cognitive behavioral therapy for insomnia (CBT-I) through software, thereby mitigating the safety concerns linked to prolonged drug dependency.

This segment has gained significant credibility through recent regulatory and reimbursement advancements crucial for its commercial viability and patient accessibility. As reported by Healthcare Brew in April 2025, the Centers for Medicare and Medicaid Services (CMS) introduced new billing codes effective January 2025, enabling healthcare providers to claim reimbursement for digital mental health treatments. This integration of digital interventions into established payment systems is a crucial impetus, encouraging physician adoption and fostering consistent revenue growth in the digital sleep health sector.

Market Challenges

A significant obstacle impeding the expansion of the global insomnia treatment market stems from the safety profiles and dependency risks inherent in traditional pharmacotherapy. The market experiences considerable pushback due to adverse effects associated with long-term use of sedative-hypnotics, including cognitive impairment, the potential for addiction, and persistent daytime drowsiness. These safety issues substantially reduce patient willingness to continue treatment and make physicians reluctant to prescribe such medications for ongoing maintenance, consequently restricting the potential customer base and consistent revenue for drug companies.

This challenge is exacerbated by new research that heightens both regulatory and public examination. In 2025, the American Heart Association reported studies linking the extended use of specific sleep aids to an 89% increased risk of incident heart failure in chronic insomnia patients. Such evidence highlights the severity of the safety concern, reinforcing skepticism towards pharmaceutical interventions and compelling the industry to navigate a more intricate and stringent regulatory landscape, which directly slows market growth.

Market Trends

A notable market trend is the move towards Dual Orexin Receptor Antagonists (DORAs), which signifies an evolution beyond conventional sedative-hypnotics that generally suppress the central nervous system. In contrast to Z-drugs that induce general sedation, DORAs precisely target and block wake-promoting neuropeptides, thereby inhibiting wakefulness while maintaining natural sleep patterns. This mechanism alleviates worries about dependency and cognitive impairment, leading to swift adoption by clinicians seeking long-term maintenance therapies. The commercial success of this shift is clear from the strong performance of leading products; Eisai Co., Ltd.'s 'Consolidated Financial Report for Fiscal 2024' (May 2025) showed that revenue for its DORA treatment, Dayvigo, soared to ¥53.8 billion, representing a 128.6% increase year-on-year.

Another significant trend is the increasing proliferation of employer-sponsored sleep wellness programs, spurred by businesses recognizing the crucial link between sleep health and workforce productivity. Companies are progressively incorporating sleep management solutions into their employee benefit offerings to mitigate presenteeism and lower healthcare expenditures. This corporate investment is justified by data illustrating the financial impact of untreated sleep deprivation. For instance, ResMed's 'Fifth Annual Global Sleep Survey' (February 2025) revealed that 70% of employed individuals across 13 markets had taken a sick day specifically due to poor sleep at least once in their career, motivating businesses to fund preventative sleep interventions.

Key Market Players

• Merck & Co
• Pfizer Inc.
• Abbott Laboratories
• Genentech Inc.
• LGM Pharma
• Sigma Aldrich Corp.
• Sanofi S.A
• Takeda Pharmaceuticals Co. Ltd.
• Eisai Ltd.
• Idorsia Pharmaceuticals Apotex Corp

Report Scope

In this report, the Global Insomnia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Insomnia Treatment Market, by Type:

• Acute Insomnia Chronic Insomnia
• Onset Insomnia
• Maintenance Insomnia
• Behavioral Insomnia of Childhood

Insomnia Treatment Market, by Drugs:

• Eszopiclone
• Ramelteon
• Zaleplon
• Zolpidem
• Estazolam
• Others

Insomnia Treatment Market, by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Insomnia Treatment Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Insomnia Treatment Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.